Table 4.

Cost (Direct + Indirect) of Iron Therapy in Ferrous Sulphate (FS) and Iron Polymaltose Complex (IPC) Groups (data expressed as Rs^* [mean ± SD])

Cost†	FS (Rs)	IPC (Rs)	Difference between the groups (95% CI)‡	P Value¶
Total cost	1405.12 ± 93.60	1454.33 ± 73.85	49.21 ± 28.12 (17.02–81.4)	.05
Drug cost	169.98 ± 75.51	237.08 ± 47.25	67.21 ± 36.15 (42.9–91.3)	< .001
Investigation cost	711.53 ± 47.08	715.62 ± 44.30	3.9 ± 2.7 (−4.02–12.2)	.23
ADR-related treatment cost	13.05 ± 2.08	6.84 ± 0.94	5.78 ± 1.64 (3–9.42)	< .001
Cost due to hospital visits	317.30 ± 309.6	310.25 ± 245.93	6.15 ± 1.7 (2.17–8.65)	.34
Cost due to loss of work	203.26 ± 35.7	213.54 ± 30.83	9.29 ± 1.54 (5-13.69)	.19

^*1 US $ = 42 Rs

^†Direct cost = drug cost + investigation cost + ADR-related treatment cost; indirect cost = cost due to visits + cost due to loss of work

^‡Figures in parentheses are 95% CI.

^¶P value represents difference in cost between groups

All values are expressed as mean ± SD.

ADR = adverse drug reaction.